Enalaprilat: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "5 mg" to "5mg") |
(Text replacement - "*Hyperkalemia" to "*Hyperkalemia") |
||
| Line 29: | Line 29: | ||
*Angioedema | *Angioedema | ||
===Common=== | ===Common=== | ||
*Hyperkalemia | *[[Hyperkalemia]] | ||
*Nausea | *Nausea | ||
*Headache | *Headache | ||
Revision as of 15:22, 24 September 2016
Administration
- Type: ACE inhibitor
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Vasotec
Adult Dosing
- 1.25-5mg IV q6h
- 0.625mg IV initially, with repeated dose of 0.625mg if inadequate response for the following patients:
- CrCl <30
- Severe volume or salt depletion, recent HD, or concomitant diuretic use
- CHF
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Angioedema history (ACEi-induced, hereditary, or idiopathic)
Adverse Reactions
Serious
- Myocardial infarction
- Liver failure
- Angioedema
Common
- Hyperkalemia
- Nausea
- Headache
Pharmacology
- Half-life: ~11h
- Metabolism:
- Excretion: Renal. Dialyzable
Mechanism of Action
- Inhibits angiotensin converting enzyme, blocking conversion of angiotensin I to angiotensin II.
